Fig. 4: ATR suppresses DNA damage-induced A3A expression.
a BICR6 cells were treated with HU (2 mM) and A3A mRNA level was analyzed at the indicated times. Mean values ± SD (n = 3). b BICR6 cells were treated with HU (2 mM), ATRi (1 μM; VE-821), ATRi#2 (0.5 μM; AZD6738), or the combinations of these drugs for 32 h and the level of A3A was monitored by RT-qPCR. Mean values ± SD (n = 3). **P < 0.01 (two-tailed Welch t-test). c Level of A3A was analyzed by western blotting 48 h following the indicated treatment. d The level of edited DDOST558C>U in BICR6 cells was quantified by ddPCR assay 72 h after treatment. Mean values ± SD (n = 4). **P < 0.01 (two-tailed Welch t-test). e A3A-deamination activity from BICR6 cell extracts treated with HU + ATRi on a DNA stem-loop substrate containing an ApC motif. f–h BICR6 cells were treated with APH (0.5 μg/mL for 32 h), IR (10 Gy for 72 h), or GEM (0.5 μM for 32 h) in combination with ATRi (1 μM; VE-821). A3A mRNA level was monitored by RT-qPCR. Mean values ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 (two-tailed Welch t-test). i A3A expression was analyzed by RT-qPCR after 32 h of HU treatment in combination with Chk1i (2 μM). Mean values ± SD (n = 3). *P < 0.05 (two-tailed Welch t-test). j MCF10A cells were treated with HU + ATRi for 32 h and released into drug-free media for the indicated time. Mean values ± SD (n = 3). Source data are provided as a Source Data file.
